NZ335246A - Substituted carbazole or hydrogenated carbazole derivatives; useful for inhibiting sPLA2 (human non-pancreatic secretory phospholipase A2) mediated release of fatty acids for conditions such as septic shock - Google Patents

Substituted carbazole or hydrogenated carbazole derivatives; useful for inhibiting sPLA2 (human non-pancreatic secretory phospholipase A2) mediated release of fatty acids for conditions such as septic shock

Info

Publication number
NZ335246A
NZ335246A NZ335246A NZ33524697A NZ335246A NZ 335246 A NZ335246 A NZ 335246A NZ 335246 A NZ335246 A NZ 335246A NZ 33524697 A NZ33524697 A NZ 33524697A NZ 335246 A NZ335246 A NZ 335246A
Authority
NZ
New Zealand
Prior art keywords
phenyl
alkyl
compound
arthritis
benzyl
Prior art date
Application number
NZ335246A
Other languages
English (en)
Inventor
Nicholas James Bach
Robert Delane Dillard
Susan Elizabeth Draheim
John Michael Morin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NZ335246A publication Critical patent/NZ335246A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • C07F9/5728Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Fats And Perfumes (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
NZ335246A 1996-10-30 1997-10-23 Substituted carbazole or hydrogenated carbazole derivatives; useful for inhibiting sPLA2 (human non-pancreatic secretory phospholipase A2) mediated release of fatty acids for conditions such as septic shock NZ335246A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2984996P 1996-10-30 1996-10-30
PCT/US1997/019183 WO1998018464A1 (en) 1996-10-30 1997-10-23 Substituted tricyclics

Publications (1)

Publication Number Publication Date
NZ335246A true NZ335246A (en) 2001-09-28

Family

ID=21851210

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ335246A NZ335246A (en) 1996-10-30 1997-10-23 Substituted carbazole or hydrogenated carbazole derivatives; useful for inhibiting sPLA2 (human non-pancreatic secretory phospholipase A2) mediated release of fatty acids for conditions such as septic shock

Country Status (26)

Country Link
EP (1) EP0839806B1 (https=)
JP (1) JP2001503055A (https=)
KR (1) KR20000049210A (https=)
CN (1) CN1233176A (https=)
AR (1) AR010050A1 (https=)
AT (1) ATE244703T1 (https=)
AU (1) AU734096B2 (https=)
BR (1) BR9713261A (https=)
CA (1) CA2269203A1 (https=)
CO (1) CO4920250A1 (https=)
CZ (1) CZ136899A3 (https=)
DE (1) DE69723393T2 (https=)
DK (1) DK0839806T3 (https=)
EA (1) EA003992B1 (https=)
ES (1) ES2202560T3 (https=)
ID (1) ID18685A (https=)
IL (1) IL129481A0 (https=)
NO (1) NO314899B1 (https=)
NZ (1) NZ335246A (https=)
PE (1) PE10999A1 (https=)
PL (1) PL332896A1 (https=)
PT (1) PT839806E (https=)
TR (1) TR199900956T2 (https=)
TW (1) TW513428B (https=)
WO (1) WO1998018464A1 (https=)
YU (1) YU19299A (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301586A1 (en) * 1997-08-28 1999-03-04 William Louis Macias Method for treatment of non-rheumatoid arthritis
HUP0102981A3 (en) 1998-03-31 2002-10-28 Shionogi & Co Pyrrolo[1,2-a]pyrazine derivatives and pharmaceutical compositions thereof
IL129484A0 (en) * 1998-04-17 2000-02-29 Lilly Co Eli Substituted tricyclics
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
BR9910095A (pt) 1998-05-01 2000-12-26 Lilly Co Eli Compostos inibidores de spla2 para tratamento de doença
WO1999059999A1 (en) 1998-05-21 1999-11-25 Shionogi & Co., Ltd. PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES HAVING sPLA2 INHIBITORY EFFECT
AU6004799A (en) 1998-10-14 2000-05-01 Shionogi & Co., Ltd. Remedies or preventives for ischemic reflow failure
US6448284B1 (en) * 1998-12-22 2002-09-10 Eli Lilly And Company Substituted tricyclics
AU6015600A (en) 1999-07-19 2001-02-05 Shionogi & Co., Ltd. Tricyclic compounds having spla2-inhibitory activities
US6673781B1 (en) 1999-08-02 2004-01-06 Shionogi & Co., Ltd. Tricyclic compounds having sPLA2-inhibitory activities
WO2001014378A1 (en) 1999-08-23 2001-03-01 Shionogi & Co., Ltd. PYRROLOTRIAZINE DERIVATIVES HAVING sPLA2-INHIBITORY ACTIVITIES
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
US6756376B1 (en) 1999-11-15 2004-06-29 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities
JP2003519198A (ja) * 2000-01-06 2003-06-17 イーライ・リリー・アンド・カンパニー 炎症性疾患および呼吸器疾患の処置のための併用療法
US6967200B2 (en) 2000-06-29 2005-11-22 Shionogi & Co., Ltd. Remedies for cirrhosis
WO2002000621A1 (en) 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
EP1345898A2 (en) 2000-12-18 2003-09-24 Eli Lilly And Company Teracyclic carbazole derivates and their use as spla2 inhibitors
TWI314457B (https=) * 2001-03-19 2009-09-11 Shionogi & Co
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
WO2006046779A1 (ja) 2004-10-29 2006-05-04 Zeria Pharmaceutical Co., Ltd. カルバゾール誘導体、その溶媒和物、又は薬学的に許容されるその塩
WO2016203468A1 (en) * 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
CN112409493B (zh) * 2020-08-12 2022-09-30 浙江工业大学 一种重组融合酶及其在乙醛酸甲酯合成中的应用
US12208031B2 (en) 2020-10-21 2025-01-28 Purewick Corporation Adapters for fluid collection devices
US12440370B2 (en) 2020-10-21 2025-10-14 Purewick Corporation Apparatus with compressible casing for receiving discharged urine
US12257174B2 (en) 2020-10-21 2025-03-25 Purewick Corporation Fluid collection assemblies including at least one of a protrusion or at least one expandable material

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3479391A (en) * 1966-10-03 1969-11-18 Squibb & Sons Inc Delta**3,14-17alpha-hydroxy-norprogesterone and esters
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors

Also Published As

Publication number Publication date
DE69723393T2 (de) 2004-06-09
DK0839806T3 (da) 2003-10-27
EP0839806A1 (en) 1998-05-06
EA003992B1 (ru) 2003-12-25
CN1233176A (zh) 1999-10-27
EP0839806B1 (en) 2003-07-09
BR9713261A (pt) 2000-03-28
NO314899B1 (no) 2003-06-10
AU5149498A (en) 1998-05-22
YU19299A (sh) 2000-03-21
DE69723393D1 (de) 2003-08-14
AR010050A1 (es) 2000-05-17
CA2269203A1 (en) 1998-05-07
CZ136899A3 (cs) 1999-09-15
ID18685A (id) 1998-04-30
EA199900305A1 (ru) 1999-12-29
ATE244703T1 (de) 2003-07-15
AU734096B2 (en) 2001-06-07
JP2001503055A (ja) 2001-03-06
TR199900956T2 (xx) 1999-07-21
WO1998018464A1 (en) 1998-05-07
TW513428B (en) 2002-12-11
CO4920250A1 (es) 2000-05-29
PL332896A1 (en) 1999-10-25
PE10999A1 (es) 1999-02-10
NO991831L (no) 1999-06-21
ES2202560T3 (es) 2004-04-01
NO991831D0 (no) 1999-04-16
KR20000049210A (ko) 2000-07-25
IL129481A0 (en) 2000-02-29
PT839806E (pt) 2003-11-28

Similar Documents

Publication Publication Date Title
AU734096B2 (en) Substituted tricyclics
AU753436B2 (en) Substituted tricyclics
JP2001503055A5 (https=)
US6177440B1 (en) Substituted tricyclics
CA2195569A1 (en) 1h-indole-1-functional spla2 inhibitors
EP1156050B1 (en) Substituted tricyclics useful in sPLA2 induced diseases
US6713645B1 (en) Substituted tricyclics
US6448284B1 (en) Substituted tricyclics
US6933313B2 (en) Substituted carbazoles as inhibitors of sPLA2
HK1010546A (en) Substituted tricyclics
HUP9903545A2 (hu) Helyettesített triciklusos vegyületek, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
HK1024912A (en) Substituted carbazoles, process for their preparation and their use as spla2 inhibitors
HK1024911A (en) Substituted carbazoles, process for their preparation and their use as spla2 inhibitors
MXPA99003587A (es) Compuestos triciclicos substituidos

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed